Inactive Instrument

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

15/08	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	31Cr 27Cr 25Cr 23Cr 43Cr 2.95TCr 43Cr 293.66Cr 115.09Cr 1.48TCr 115.67Cr 113.16Cr 4.92TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	40Cr 35Cr 33Cr 30Cr 56Cr 3.87TCr 57Cr 385.25Cr 150.98Cr 1.94TCr 151.74Cr 148.45Cr 6.45TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	11.1x
Free-Float	96.87%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc

15/08	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/25/31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/25/27	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/25/24	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/25/27	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

15/08	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
06/08	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
08/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
02/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
16/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.17%	+3.62%	+70.94%	+109.68%	7.33TCr
ARGENX SE	+1.73%	+13.43%	+57.10%	+90.54%	6.2TCr
INSMED INCORPORATED	+0.11%	-3.10%	+0.94%	+491.16%	2.8TCr
WUXI BIOLOGICS (CAYMAN) INC.	+5.24%	+5.33%	+57.01%	+17.77%	2.41TCr
BIONTECH SE	+1.26%	-0.05%	-17.59%	-15.96%	2.3TCr
PHARMAESSENTIA CORPORATION	-0.71%	+5.26%	+241.94%	+427.03%	1.83TCr
GENMAB A/S	0.00%	+5.62%	+40.50%	-15.26%	1.95TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.83%	+2.65%	+25.00%	+592.85%	1.59TCr
EXELIXIS, INC.	+1.53%	+3.49%	+40.68%	+151.75%	1.3TCr
Average	+1.39%	+1.24%	+57.39%	+205.51%	3.08TCr
Weighted average by Cap.	+1.22%	+3.43%	+57.33%	+167.51%

	2026 *	2027 *
Net sales	-	3.89Cr 3.36Cr 3.16Cr 2.88Cr 5.41Cr 373.04Cr 5.49Cr 37Cr 15Cr 186.57Cr 15Cr 14Cr 621.45Cr
Net income	-	-
Net Debt	9.61Cr 8.3Cr 7.81Cr 7.1Cr 13Cr 920.57Cr 14Cr 92Cr 36Cr 460.41Cr 36Cr 35Cr 1.53TCr	12Cr 11Cr 10Cr 9.23Cr 17Cr 1.2TCr 18Cr 119.09Cr 47Cr 598.7Cr 47Cr 46Cr 1.99TCr

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile